NDA 212028 · Eisai INC
Dayvigo
Lemborexant · Oral · Orexin Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Feb 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 20, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
48
7 Phase 3, 11 recruiting
FAERS reports
2,946
2,287 serious, 370 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 24, 2025.
DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies ( 14.1 )] . DAYVIGO is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )
Mechanism: The mechanism of action of lemborexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 20, 2023 Supplement 8 · Efficacy LetterLabel
- Dec 20, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
- DAYVIGO · LEMBOREXANT 10MG · TABLET, ORAL · Prescription
- DAYVIGO · LEMBOREXANT 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lemborexant" as an intervention, any sponsor and status, largest first.
- Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)Pivotal-lookingCompleted
Eisai Inc.Eisai
NCT02783729 · 1,006 participants · Start May 31, 2016 · Primary completion Jan 30, 2018
Drug: Lemborexant; Lemborexant and 3 more · For: Insomnia
Sites: Jasper, Alabama; Glendale, Arizona; Little Rock, Arkansas · 102 sites in all
- Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled TrialPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07695285 · 992 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2029
Drug: Lemborexant Pill; Placebo tablet · For: Postoperative Delirium
- Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)Pivotal-lookingCompleted
Eisai Inc.Eisai
NCT02952820 · 971 participants · Start Nov 15, 2016 · Primary completion Jan 8, 2019
Drug: lemborexant; Placebo · For: Insomnia Disorder
Sites: Chandler, Arizona; Rogers, Arkansas; Beverly Hills, California · 114 sites in all
- DORA and LP in Alzheimer's Disease BiomarkersPivotal-lookingRecruiting
University of MinnesotaAcademic, hospital or other
NCT06274528 · 201 participants (planned) · Start Mar 11, 2024 · Primary completion Mar 31, 2030
Drug: Lemborexant 10 mg; Lemborexant 20mg and 1 more · For: Alzheimer Disease
Sites: St Louis, Missouri
- A Study of Lemborexant in Chinese Participants With Insomnia DisorderPivotal-lookingCompleted
Eisai Co., Ltd.Eisai
NCT04549168 · 194 participants · Start Nov 6, 2020 · Primary completion Mar 17, 2023
Drug: Lemborexant; Placebo · For: Sleep Initiation and Maintenance Disorders
Sites: Beijing, China; Guangzhou, China; Shijiazhuang, China · 23 sites in all
- Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep ApneaPivotal-lookingCompleted
Eisai Inc.Eisai
NCT03471871 · 146 participants · Start Feb 21, 2018 · Primary completion Aug 3, 2018
Drug: Placebo; Lemborexant 10 mg and 3 more · For: Obstructive Sleep Apnea; Healthy Subjects
Sites: Glendale, Arizona; Phoenix, Arizona; San Diego, California · 11 sites in all
- Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic SurgeryPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07811401 · 130 participants (planned) · Start Oct 8, 2026 · Primary completion Dec 31, 2027
Drug: Lemborexant 5 mg; Placebo · For: Postoperative Sleep Disturbance; Thoracoscopic Surgery
- Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain StimulationPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07903038 · 128 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 31, 2027
Drug: Lemborexant 5 mg; Placabo · For: Parkinson Disease (PD); Sleep Initiation and Maintenance Disorders; Deep Brain Stimulation
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective332
- off label use215
- suicide attempt175
- condition aggravated157
- suicidal ideation156
- somnolence149
- fall111
- nausea104
- dizziness97
- headache97
- insomnia94
- adverse drug reaction92
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 199 |
| 2021 | 320 |
| 2022 | 376 |
| 2023 | 420 |
| 2024 | 554 |
| 2025 | 604 |
| 2026 | 469 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dayvigo (Lemborexant)
2024 spending
$21.0M
Beneficiaries
14,593
57,890 claims
Per beneficiary
$1,437
$11.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,189,295 |
| 2021 | $9,100,845 |
| 2022 | $13,911,430 |
| 2023 | $16,516,063 |
| 2024 | $20,975,238 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Citrome L, et al. · Transl Psychiatry 2025 · Comparative Study, Network Meta-Analysis
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
Yue JL, Chang XW, Zheng JW, et al. · Sleep Med Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R, Murphy P, Zammit G, et al. · JAMA Netw Open 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H, O'Leary B, Adena M, et al. · J Manag Care Spec Pharm 2021 · Comparative Study, Network Meta-Analysis
- Pharmacotherapies for sleep disturbances in dementia.
McCleery J, Sharpley AL · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.